Incretin Based Drugs Market Analysis By Industry Size, Share, Revenue Growth and Demand Forecast To 2031

The global incretin-based drugs market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period (2024-2031). Increased research activity, government initiatives to promote disease awareness, and research grants are primary factors which are expected to fuel the global incretin-based drug market’s growth over the forecast period. Furthermore, rising government spending in R&D activities, as well as new product releases by numerous prominent companies, are expected to further propel the diabetes medicines market.

Get Free Sample link @ https://www.omrglobal.com/request-sample/incretin-based-drugs-market

For instance, in October 2021, Glenmark launched drug in combination of various incretin based drug types including remogliflozin, vildagliptin, metformin fixed-dose combination (FDC) at an affordable cost for adults with type-2 diabetes. Among others, India is the first country to get access to this FDC drug. Glenmark had received an approval for the drug from the Drug Controller General of India (DCGI) for manufacturing and marketing back in September 2021. The new drug launched combines two or more active incretin based drugs in a single dosage form and can manage most of the pathophysiology in managing uncontrolled type-2 Diabetes. Further, in April 2019, Glenmark developed Remogliflozin, an oral anti-diabetic medicine that is deemed helpful in treating individuals with type-2 diabetes mellitus. Thus, increased product development in emerging countries along with rising healthcare expenditure will bolster the growth of the market.

Full report of Incretin Based Drugs Market available @ https://www.omrglobal.com/industry-reports/incretin-based-drugs-market

Market Coverage

Segment Covered- 

• By Drug Type
• By Route of Administration
• By Distribution Channel

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- including AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Co., GlaxoSmithKline plc., Merck & Co., and others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o             Deviation from the pre-COVID-19 forecast

o             Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Incretin Based Drugs Market Report Segment

By Drug Type

• Glucagon-like Peptide-1 Receptor Agonists
• Dipeptidyl Peptidase-4 Inhibitor

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/incretin-based-drugs-market

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.